DE69835426D1 - Aktivierung von peptiden - Google Patents

Aktivierung von peptiden

Info

Publication number
DE69835426D1
DE69835426D1 DE69835426T DE69835426T DE69835426D1 DE 69835426 D1 DE69835426 D1 DE 69835426D1 DE 69835426 T DE69835426 T DE 69835426T DE 69835426 T DE69835426 T DE 69835426T DE 69835426 D1 DE69835426 D1 DE 69835426D1
Authority
DE
Germany
Prior art keywords
peptides
activation
peptide
reversible
assays
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69835426T
Other languages
English (en)
Other versions
DE69835426T2 (de
Inventor
Singh Ajoula
John Clarke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ANMAT TECHNOLOGY Ltd
Original Assignee
ANMAT TECHNOLOGY Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ANMAT TECHNOLOGY Ltd filed Critical ANMAT TECHNOLOGY Ltd
Publication of DE69835426D1 publication Critical patent/DE69835426D1/de
Application granted granted Critical
Publication of DE69835426T2 publication Critical patent/DE69835426T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43572—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from bees
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/586—Liposomes, microcapsules or cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69835426T 1997-03-18 1998-03-18 Aktivierung von peptiden Expired - Lifetime DE69835426T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9705519 1997-03-18
GBGB9705519.8A GB9705519D0 (en) 1997-03-18 1997-03-18 Activation of peptides
PCT/GB1998/000799 WO1998041535A2 (en) 1997-03-18 1998-03-18 Activation of peptides

Publications (2)

Publication Number Publication Date
DE69835426D1 true DE69835426D1 (de) 2006-09-14
DE69835426T2 DE69835426T2 (de) 2007-03-29

Family

ID=10809387

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69835426T Expired - Lifetime DE69835426T2 (de) 1997-03-18 1998-03-18 Aktivierung von peptiden

Country Status (8)

Country Link
EP (1) EP0979243B1 (de)
JP (1) JP2001522353A (de)
AT (1) ATE334999T1 (de)
AU (1) AU6509898A (de)
CA (1) CA2284107C (de)
DE (1) DE69835426T2 (de)
GB (1) GB9705519D0 (de)
WO (1) WO1998041535A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100196D0 (en) * 2001-01-04 2001-02-14 Anmat Technology Ltd Peptides
WO2007113839A2 (en) 2006-04-03 2007-10-11 Given Imaging Ltd. Device, system and method for in-vivo analysis
JP5275217B2 (ja) * 2006-04-03 2013-08-28 ギブン イメージング リミテッド 生体内分析のためのシステム
WO2009102859A2 (en) 2008-02-14 2009-08-20 3M Innovative Properties Company Polypeptides for microbial detection
US8835361B2 (en) * 2010-06-01 2014-09-16 The Curators Of The University Of Missouri High-throughput quantitation of crop seed proteins
ES2758451T3 (es) * 2012-09-19 2020-05-05 Gemvax & Kael Co Ltd Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado
AR111893A1 (es) * 2017-05-26 2019-08-28 Plant Health Care Inc Péptidos derivados de inductores de la respuesta de hipersensibilidad y su uso
CN110498848B (zh) * 2019-09-10 2020-05-12 中国医学科学院基础医学研究所 一种蜂毒肽变体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517303A (en) * 1982-10-20 1985-05-14 E. I. Du Pont De Nemours And Company Specific binding assays utilizing analyte-cytolysin conjugates
US4874710A (en) * 1986-02-20 1989-10-17 Becton Dickinson And Company Assay and product in which binder and liposomes are supported on a solid support
AUPN861496A0 (en) * 1996-03-13 1996-04-04 Commonwealth Scientific And Industrial Research Organisation Lytic peptides

Also Published As

Publication number Publication date
WO1998041535A3 (en) 1998-12-23
JP2001522353A (ja) 2001-11-13
AU6509898A (en) 1998-10-12
EP0979243A2 (de) 2000-02-16
CA2284107A1 (en) 1998-09-24
GB9705519D0 (en) 1997-05-07
EP0979243B1 (de) 2006-08-02
ATE334999T1 (de) 2006-08-15
WO1998041535A2 (en) 1998-09-24
DE69835426T2 (de) 2007-03-29
CA2284107C (en) 2008-06-10

Similar Documents

Publication Publication Date Title
DE69900746T2 (de) Gesteuerte verabreichung von peptiden oder proteinen
DE69518820T2 (de) Rotogranulat und Beschichtung von Acetaminophen, Pseudoephedrin, Chlorpheniramin und, gegebenenfalls, Dextromethorphan
NO985975D0 (no) Blandinger og fremgangsmÕter for frembringelse av farmakologisk aktive preparater og anvendelser derav
DE68917729D1 (de) Reinigung und verabreichung von dns-reparatur-enzymen.
DE3787002T2 (de) Synthetische Peptide, die zelluläre Immunität gegen den AIDS-Virus und dessen Proteine erzeugen.
NO971875L (no) Cathepsin 02 protease
DE69938786D1 (de) Die verwendung von peptiden von il-2 und peptid-derivaten als therapeutische wirkstoffe
DE68903576T2 (de) Signalpeptide, die in hefe wirksam sind und ihre verwendung zur sekretorischen expression von heterologen proteinen.
ID19229A (id) Metode dan alat penginput huruf
DE68924145D1 (de) Generation von Kollationierungssätzen und Steuerung.
DE69835426D1 (de) Aktivierung von peptiden
DE69702554D1 (de) Aminopeptidase GX und damit Hydrolysierungsverfahren von Proteine
ID17999A (id) Amida-amida asam alpha-amino, permbuatan dan penggunaannya secara terapi
FR2733418B1 (fr) Nouvelles associations comprenant du (-) hydroxycitrate et presentant notamment de nouvelles activites therapeutiques
DE68915154T2 (de) Anwendung von gegen retroviren aktiven wirkstoffen und so erhaltene produkte.
NO973230D0 (no) Nye peptider, deres fremstilling og anvendelse
FI953257A0 (fi) Rekombinanttinen ihmisen prostaspesifinen antigeenRekombinanttinen ihmisen prostaspesifinen antigeeni ja sen käytöt i ja sen käytöt
ATE192163T1 (de) Peptide, analoge und ihre mischungen zur detektion und erzeugung von antikörpern gegen die e1 und e2 proteine des rubella virus
DE69609510D1 (de) Bispezifische moleküle gegen allergie
DE68914544D1 (de) Peptid und Wirkstoff gegen Dementia.
NL1000332C1 (nl) Graduele chemische modificatie van biologisch actieve peptiden en eiwitten.
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff
FI963664A0 (fi) Tuhoamismenetelmä, erityisesti täydellinen polttaminen
DE758903T1 (de) Konzentrate von kryopräziptiertem, nativem fibrinogen
ID15808A (id) Penggunaan protease dibidang kedokteran

Legal Events

Date Code Title Description
8364 No opposition during term of opposition